Their analysis revealed trends toward development of a variety of non-canonical mAbs, including antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies and antibody fragments and/or domains. They found substantial diversity in the antibody sequence source, isotype, carbohydrate residues, targets and mechanisms of action (MOA). Although well-validated targets, such as epidermal growth factor receptor (EGFR) and CD20, continue to provide opportunities for companies, they found notable trends toward targeting less-well-validated antigens and exploration of innovative MOA such as the generation of anticancer immune responses or recruitment of cytotoxic T cells.